Namita Thapar’s Emcure Pharma Soars 38,200% on NSE Debut
As Emcure Pharma debuted on the NSE with a 31% premium, well-known investor from Shark Tank India and Emcure Pharmaceuticals executive director Namita Thapar is witnessing incredible returns on her money. Originally ₹2.19 crore, Thapar’s initial investment in the company has now risen to almost ₹671 crore following the IPO. Starting on the NSE at…